USPTO serial 79414045
SYNI
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 14, 2025
- Examiner
- GARCIA, CLAUDIA
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SYNI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Stephen Drysdale
908/233 Pyrmont StreetPyrmont, 2009AUSTRALIAGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Food supplements, namely, anti-oxidants; capsules sold empty for pharmaceutical purposes; capsules sold empty for veterinary pharmaceutical preparations; chemical preparations for pharmaceutical use to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; collagen based medicated supplements for use as nutritional supplements; decoctions for pharmaceutical purposes to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; antioxidants in the nature of dietary supplements; dietary protein supplements; dietary supplements; dietary supplements for animals; dietary supplements with a cosmetic effect; effervescent pharmaceutical preparations to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; food supplements for medical purposes to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; herbal dietary supplements; dietary nutritional supplements; nutritional supplements; plant extracts, other than essential oils, being dietary supplements; medicated lozenges for pharmaceutical purposes; skin lotions for pharmaceutical purposes; pharmaceutical preparations to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; pharmaceutical preparations containing vitamins to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; pharmaceutical preparations for health care to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; pharmaceutical preparations for human use to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; pharmaceutical preparations for oral use to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; pharmaceutical preparations for skin care; pharmaceutical preparations for veterinary use to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; chemical products in the nature of chemical preparations for pharmaceutical use to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; natural pharmaceutical products to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; pharmaceutical products to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; tablets being pharmaceuticals to support nicotinamide adenine dinucleotide production, cell metabolism and energy production, maintain cardiovascular health, support blood capillary health, and relieve inflammation of joints; food supplements for animals in the nature of vitamins; vitamin supplements; dietary food supplements; nutritional drinks being dietary food supplements; food supplements in the nature of dietary supplements. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 25, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 18, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jun 1, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| May 31, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Apr 24, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 24, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jan 14, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 14, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Oct 14, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 26, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 26, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 20, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 18, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 14, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 14, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 14, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 5, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 24, 2025 | ALIE | ASSIGNED TO LIE | — |
| Jun 14, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 14, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 11, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 10, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 9, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 14, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 14, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 14, 2025 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jan 2, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |